Gemfibrozil

CHEMBL457 Phase 4 Одобрено Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

250.3 g/mol

LogP

3.8

Phase

4

A fibrate medication used to lower triglyceride levels and raise HDL (good) cholesterol by activating receptors in the liver that regulate fat metabolism. It is used in patients at risk for cardiovascular disease or pancreatitis due to very high triglycerides, and may also benefit patients with chronic kidney disease affecting lipid levels. Regular monitoring of liver function and muscle-related symptoms is recommended during treatment.

Молекулярная масса

250,3300 g/mol

LogP

3,80

TPSA

46,50 Å²

Правило пяти Липинского

Соответствует

Терапевтические области

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Pain Management Non-Small Cell Lung Cancer Alzheimer's Disease Multiple Sclerosis Obesity Type 2 Diabetes Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1

InChI

InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)

Molecular Formula

C15H22O3

HBD / HBA

1 / 3

Вращаемые Связи

6

Тяжёлые Атомы

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A fibrate medication used to lower triglyceride levels and raise HDL (good) cholesterol by activating receptors in the liver that regulate fat metabolism. It is used in patients at risk for cardiovascular disease or pancreatitis due to very high triglycerides, and may also benefit patients with chronic kidney disease affecting lipid levels. Regular monitoring of liver function and muscle-related symptoms is recommended during treatment.

Yes, Gemfibrozil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL457. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3463. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Ищете информацию, доступную для пациентов?

Gemfibrozil на PillFYI

Структура

Краткие Данные

Формула: C15H22O3
Синонимы: 1

Внешние ссылки

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.